This company is no longer active
ARCA biopharma Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Tom Keuer
Algemeen directeur
US$400.8k
Totale compensatie
| Percentage CEO-salaris | 84.8% |
| Dienstverband CEO | 9.7yrs |
| Eigendom CEO | 0.3% |
| Management gemiddelde ambtstermijn | geen gegevens |
| Gemiddelde ambtstermijn bestuur | 7.5yrs |
Recente managementupdates
Recent updates
Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth
Apr 04
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?
Sep 24ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play
May 03Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?
Mar 18Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?
Nov 27Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation
Jul 15Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation
Mar 30Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19
Dec 15We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth
Dec 15
ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment
Nov 24ARCA biopharma reports Q3 results
Nov 02Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$7m |
| Mar 31 2024 | n/a | n/a | -US$6m |
| Dec 31 2023 | US$401k | US$340k | -US$5m |
| Sep 30 2023 | n/a | n/a | -US$5m |
| Jun 30 2023 | n/a | n/a | -US$6m |
| Mar 31 2023 | n/a | n/a | -US$8m |
| Dec 31 2022 | US$449k | US$340k | -US$10m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | -US$17m |
| Mar 31 2022 | n/a | n/a | -US$18m |
| Dec 31 2021 | US$421k | US$339k | -US$19m |
| Sep 30 2021 | n/a | n/a | -US$19m |
| Jun 30 2021 | n/a | n/a | -US$16m |
| Mar 31 2021 | n/a | n/a | -US$13m |
| Dec 31 2020 | US$631k | US$285k | -US$10m |
| Sep 30 2020 | n/a | n/a | -US$6m |
| Jun 30 2020 | n/a | n/a | -US$5m |
| Mar 31 2020 | n/a | n/a | -US$5m |
| Dec 31 2019 | US$304k | US$283k | -US$5m |
| Sep 30 2019 | n/a | n/a | -US$6m |
| Jun 30 2019 | n/a | n/a | -US$6m |
| Mar 31 2019 | n/a | n/a | -US$7m |
| Dec 31 2018 | US$327k | US$303k | -US$8m |
| Sep 30 2018 | n/a | n/a | -US$11m |
| Jun 30 2018 | n/a | n/a | -US$13m |
| Mar 31 2018 | n/a | n/a | -US$17m |
| Dec 31 2017 | US$457k | US$302k | -US$18m |
Compensatie versus markt: De totale vergoeding ($USD 400.80K ) Tom } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 653.78K ).
Compensatie versus inkomsten: De vergoeding van Tom is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Tom Keuer (65 yo)
9.7yrs
Tenure
US$400,802
Compensatie
Mr. Thomas A. Keuer, also known as Tom, serves as President & Principal Executive Officer of ARCA Biopharma, Inc. since April 3, 2024 and has been the Chief Operating Officer since December 1, 2014. Mr. Ke...
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Independent Director | 17.3yrs | US$162.50k | 0% $ 0 | |
| Independent Director | 7.5yrs | US$150.00k | 0% $ 0 | |
| Independent Chairman of the Board | 10.9yrs | US$195.00k | 0.34% $ 174.5k | |
| Director | 2.2yrs | US$130.00k | geen gegevens | |
| Independent Director | 1.7yrs | US$40.00k | 0% $ 0 |
7.5yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ABIO wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.5 jaar).